
Women with ovarian cancer, who experience relapses shortly after their chemotherapy treatments, could buy significant amounts of time until the next setback by being treated with the biological drug Avastin (bevacizumab).
That’s the indication of results from an international clinical study made public by Avastin manufacturer, Roche, at the recent ASCO convention.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app